Assessment of the response to imatinib in chronic myeloid leukemia patients–comparison between the FISH, multiplex and RT‐PCR methods
P Raanani, I Ben‐Bassat, S Gan… - European journal of …, 2004 - Wiley Online Library
Objective: The objective of this study was to evaluate the kinetics of molecular response in
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
Purpose: To determine the clinical significance of molecular response and relapse among
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …
patients with chronic myelogenous leukemia (CML) treated with imatinib. Experimental …
Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous …
HM Kantarjian, M Talpaz, J Cortes, S O'Brien… - Clinical cancer …, 2003 - AACR
Purpose: The purpose of our investigation was to evaluate the response and minimal
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
residual disease by quantitative competitive PCR (QC-PCR) studies in patients with chronic …
[HTML][HTML] Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
G Martinelli, I Iacobucci, G Rosti, F Pane, M Amabile… - Annals of oncology, 2006 - Elsevier
Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia
L Wang, K Pearson, JE Ferguson… - British journal of …, 2003 - Wiley Online Library
Real‐time quantitative reverse transcription‐polymerase chain reaction (Q‐RT‐PCR) is
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
increasingly used to monitor responses in chronic myeloid leukaemia (CML). The peripheral …
Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic …
T Furukawa, M Narita, T Koike, K Takai, K Nagai… - International journal of …, 2011 - Springer
This retrospective analysis investigated the prognostic value of monitoring the response to
imatinib using peripheral blood (PB) samples and the impact of the response on outcome in …
imatinib using peripheral blood (PB) samples and the impact of the response on outcome in …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - ashpublications.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
[HTML][HTML] Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic …
B Hanfstein, MC Müller, P Erben, S Schnittger… - Blood, 2010 - Elsevier
Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …
treatment has been observed in a substantial proportion of CML patients and has been …
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
M Breccia, L Cannella, C Stefanizzi… - Hematological …, 2010 - Wiley Online Library
Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …